Company Analysis Bio-Techne Corporation
1. Summary
Advantages
- The stock's return over the last year (-12.8%) is higher than the sector average (-43.68%).
Disadvantages
- Price (64.15 $) is higher than fair price (8.57 $)
- Dividends (0.4401%) are below the sector average (0.5399%).
- Current debt level 15.52% has increased over 5 years from 0.6633%.
- The company's current efficiency (ROE=8.33%) is lower than the sector average (ROE=9.39%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
20 november 02:19 Lordstown Motors reportedly in talks to sell Ohio factory to Foxconn
20 november 01:39 Foxconn, Wisconsin reach new deal on scaled back facility
20 november 00:36 iPhone maker Foxconn and Fisker working on American-made electric car
2.3. Market efficiency
| Bio-Techne Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2% | -25.1% | -4.9% |
| 90 days | -14.9% | -45.3% | 0.1% |
| 1 year | -12.8% | -43.7% | 19.4% |
TECH vs Sector: Bio-Techne Corporation has outperformed the "Healthcare" sector by 30.88% over the past year.
TECH vs Market: Bio-Techne Corporation has significantly underperformed the market by -32.24% over the past year.
Stable price: TECH is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: TECH with weekly volatility of -0.2462% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (64.15 $) is higher than the fair price (8.57 $).
Price is higher than fair: The current price (64.15 $) is 86.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (71.24) is higher than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (71.24) is higher than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (5.79) is higher than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (5.79) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (10.33) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (10.33) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (39.45) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (39.45) is higher than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -5.32% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-5.32%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (8.33%) is lower than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (8.33%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (6.29%) is higher than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (6.29%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (14.42%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (14.42%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.4401% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.4401% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 0.4401% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (29.99%) are at a comfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 12.09.2024 | HIGGINS JOHN L Director |
Purchase | 22.95 | 137 700 | 6 000 |
| 08.08.2024 | BAUMGARTNER ROBERT V Director |
Sale | 72.1 | 1 153 600 | 16 000 |
| 08.08.2024 | BAUMGARTNER ROBERT V Director |
Purchase | 22.95 | 367 200 | 16 000 |
| 07.03.2024 | Nusse Roeland Director |
Sale | 76.98 | 800 592 | 10 400 |
| 23.08.2022 | Kelderman Kim Pres. Diagnostics & Genom |
Purchase | 150.78 | 99 967 | 663 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
